Growth & profitability
- Revenue has declined 52.7% per year over the past 5 years.
- Operating margin has contracted, at -11910.1% in the latest year.
Financial health
- Total debt has grown faster than revenue (44.8% vs -52.7% per year).
MCRB Financials Seres Therapeutics, Inc.
13 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $789000 | $6M | 0.0% | -11910.1% | $865000 | — | $46M |
| 2024 | $0 | $136000 | — | — | -$149M | — | $31M |
| 2023 | $0 | -$114M | — | — | -$125M | $110M | $128M |
| 2022 | $7M | -$250M | 0.0% | -2524.0% | -$239M | $50M | $163M |
| 2021 | $145M | -$66M | 0.0% | -44.5% | -$3M | $24M | $180M |
| 2020 | $33M | -$89M | 0.0% | -265.3% | -$94M | $25M | $116M |
| 2019 | $35M | -$70M | 0.0% | -208.3% | -$78M | $25M | $65M |
| 2018 | $28M | -$99M | 0.0% | -354.8% | -$65M | — | $86M |
| 2017 | $32M | -$89M | 0.0% | -284.7% | -$80M | — | $36M |
| 2016 | $22M | -$92M | 0.0% | -426.5% | $22M | — | $55M |
| 2015 | $0 | -$55M | — | — | — | — | $74M |
| 2014 | — | -$17M | — | — | — | — | $114M |
| 2013 | — | -$6M | — | — | — | — | $2M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $358000 | -$20M | 0.0% | -5839.9% | -$16M | — | $30M |
| Dec '25 | $438000 | -$15M | 0.0% | -4424.0% | -$15M | — | $46M |
| Sep '25 | $351000 | $8M | 0.0% | -6403.7% | $2M | — | $48M |
| Jun '25 | — | -$20M | — | — | -$13M | — | $45M |
| Mar '25 | $0 | $33M | — | — | $27M | — | $59M |
| Dec '24 | $0 | -$16M | — | — | -$39M | — | $31M |
| Sep '24 | $0 | $89M | — | — | -$35M | — | $67M |
| Jun '24 | $0 | -$33M | — | — | -$40M | $110M | $71M |
| Mar '24 | $0 | -$40M | — | — | -$35M | $110M | $111M |
| Dec '23 | $64000 | -$41M | 0.0% | -57850.0% | -$48M | $110M | $128M |
| Sep '23 | $310000 | -$48M | 0.0% | -14382.6% | -$61M | $110M | $170M |
| Jun '23 | $126M | $47M | 0.0% | 39.2% | $65M | $110M | $230M |
| Mar '23 | -$522000 | -$71M | 0.0% | 13518.8% | -$81M | $50M | $95M |
| Dec '22 | $975000 | -$69M | 0.0% | -7005.8% | -$56M | $50M | $163M |
| Sep '22 | $3M | -$60M | 0.0% | -1716.2% | -$61M | $50M | $205M |
| Jun '22 | $1M | -$65M | 0.0% | -5207.6% | -$52M | $50M | $127M |
| Mar '22 | $1M | -$57M | 0.0% | -3734.2% | -$69M | $50M | $153M |
| Dec '21 | $7M | -$50M | 0.0% | -684.6% | -$53M | $24M | $180M |
| Sep '21 | $127M | $68M | 0.0% | 54.0% | $124M | $25M | $227M |
| Jun '21 | $5M | -$48M | 0.0% | -914.7% | -$42M | $25M | $74M |
Valuation over time
How the market has priced MCRB against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 58.7× (Dec '24) to 11.5× (Jun '26).
- The price-to-sales ratio has risen from 7.6× (Mar '23) to 83.3× (Jun '26).
P/E
P/S
Frequently asked questions
Is MCRB growing its revenue and profit?
Over the past 5 years, Seres Therapeutics, Inc.'s revenue has declined 52.7% per year. These are computed facts, not advice.
How much debt does MCRB have?
As of FY2025, Seres Therapeutics, Inc. reported — of total debt against $46M of cash.
What is MCRB's profit margin?
In FY2025, gross margin was —, operating margin -11910.1%, and net margin 721.9%.
What is MCRB's P/E ratio?
As of Jun '26, Seres Therapeutics, Inc. traded at a price-to-earnings ratio of about 11.5× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.